Therapeutic targeting of autophagy for renal cell carcinoma therapy

Research output: Contribution to journalArticlepeer-review

31 Scopus citations


Kidney cancer is the 7th most prevalent form of cancer in the United States with the vast majority of cases being classified as renal cell carcinoma (RCC). Multiple targeted therapies have been developed to treat RCC, but efficacy and resistance remain a challenge. In recent years, the modulation of autophagy has been shown to augment the cytotoxicity of approved RCCtherapeutics and overcome drug resistance. Inhibition of autophagy blocks a key nutrient recycling process that cancer cells utilize for cell survival following periods of stress including chemotherapeutic treatment. Classic autophagy inhibitors such as chloroquine and hydroxychloroquine have been introduced into phase I/II clinical trials, while more experimental compounds are moving forward in preclinical development. Here we examine the current state and future directions of targeting autophagy to improve the efficacy of RCC therapeutics.

Original languageEnglish (US)
Article number1185
Issue number5
StatePublished - May 2020


  • Autophagy
  • Chloroquine
  • Hydroxychloroquine
  • Renal cell carcinoma
  • Roc-325

ASJC Scopus subject areas

  • Oncology
  • Cancer Research


Dive into the research topics of 'Therapeutic targeting of autophagy for renal cell carcinoma therapy'. Together they form a unique fingerprint.

Cite this